4DMT is a clinical stage biopharma company inventing and developing innovative products to unlock the full potential of genetic medicine to treat large market and rare diseases. Our vector discovery platform Therapeutic Vector Evolution harnesses the power of directed evolution, a Nobel Prize-winning technology, with approximately one billion synthetic AAV capsid-derived sequences to invent customized and evolved vectors with improved therapeutic profiles compared to wild-type vectors. Our product design, development and manufacturing engine empowers us to efficiently create our valuable and diverse product pipeline. This combination of bold innovation and relentless execution gives 4DMT the capability to revolutionize genetic medicines and to strive for potential curative therapies. We have built a deep portfolio of genetic medicine product candidates, with five product candidates in clinical trials for seven patient populations.

We are taking genetic medicine to new heights and into new disease areas to overcome challenges not addressed by existing medicines. This incredible challenge drives our relentless and talented team. Our people are the essence of our inspiring, innovative and collaborative environment that encourages individual contributions and provides opportunities for career development. We seek the best in the industry who identify with our mission and our bold and innovative results-driven approach. Our 4 Guiding Principles drive the way we work together: 
-	Dare to Cure
-	Break Boundaries 
-	Beyond Yourself 
-	Prepare & Executive Relentlessly 

Join us in creating the future of genetic medicine.

Pappas Capital

Perceptive Advisors

Pfizer Venture Investments

QUAD Investment Management

Viking Global Investors

Longevity Vision Fund

MiraeAsset Financial Group

Berkeley Catalyst Fund (BCF)

Biotechnology Value Fund

BVF Partners

Chiesi Ventures

4D Molecular Therapeutics

4DMT is excited to be featured on BioSpace’s 2024 #BestPlacesToWork small employer list — a list of the top ranked life science employers in North America based on industry vote. Thank you, BioSpace for this honorable recognition, and our 4DMT family for making this award possible. Interested in joining our team? Learn more here: https://lnkd.in/ge8w9xnt

Thank you, Emily's Entourage! We are immensely honored to be a Dream Team Sponsor for the 2023 Scientific Symposium taking place next month. It's a privilege to stand alongside organizations like EE and work together to accelerate treatments for the final 10% of individuals with #cysticfibrosis. We are grateful for the passionate support from EE and the entire cystic fibrosis community.

We are gratified to receive additional financial and research support from the CF Foundation for our cutting edge, next-generation lung gene delivery technology!

This month, our #4DMT team will be participating in a fireside chat at the 6th Annual Evercore ISI #HealthCONx Conference. We look forward to connecting! Register for the webcast here: https://lnkd.in/e-uZM_6S
#investorconference

Last week, the 4DMT team participated at #NACFC 2023, where we shared positive data from our Phase 1/2 AEROW clinical trial of 4D-710. We are grateful for the opportunity to connect with the cystic fibrosis community and help advance new treatments for CF.

Today, we announced our third quarter financial results and operational highlights, including updates across our ophthalmology, pulmonology, and cardiology programs. Read more about our recent progress and anticipated upcoming milestones: https://lnkd.in/gpUQkv5w  #earnings

Our team was thrilled to be on-site in San Francisco this past weekend for #AAO23 to hear from colleagues and exhibitors on the latest technologies and treatments in ophthalmology.

We are thrilled to present positive interim data from Phase 1/2 AEROW clinical trial of aerosolized 4D-710 at Cystic Fibrosis Foundation’s North American Cystic Fibrosis Conference this week in Phoenix, Arizona. 
 
We also would like to warmly welcome Alan H. Cohen, MD, who has joined 4DMT as SVP, Therapeutic Area Head of Pulmonology. 
 
Finally, we are gratified to announce that the Cystic Fibrosis Foundation has increased their funding commitment under our research agreement by $2.8 million to a total of $6.3 million. The increased financial commitment brings their total historical commitment to the 4DMT CF program to over $20 million.
 
Stop by kiosk #2 to connect with our team and learn more about the latest progress with 4D-710, an investigational genetic medicine for adults with #cysticfibrosis lung disease. Read the full release here: https://lnkd.in/dgKfuVwd 
 
Register for the webcast here: https://lnkd.in/g6ztcSZR

People with #CysticFibrosis who are not amenable or do not respond to CFTR modulators deserve treatments that address the underlying cause of the disease. We are on a mission to develop a potentially transformative new therapy to treat a broad range of people with #CF. Learn about 4D-710: https://lnkd.in/gzw65bYm

Today, we announced alignment with the FDA on a plan to lift the clinical hold on our Phase 1/2 INGLAXA clinical trial for 4D-310 for Fabry disease #cardiomyopathy. In addition, we expect to share additional interim clinical data from INGLAXA for all 6 patients treated to date in Q1 2024. Read the full press release here: https://lnkd.in/gPdKNQpm 
#fabrydisease

reCAPTCHA

jQuery CDN

Gravity Forms

Mobile Optimized

New Relic

Drupal

Cloudinary

Adobe Dynamic Tag Management

Drupal 10

Adobe Marketing Cloud

President & Chief Operating Officer

Fred Kamal

Executive Chair

John Milligan

Chief Scientific Officer and Therapeutic Area Head, Ophthalmology

Peter Francis

Chief Medical Officer

Robert Fishman

Vice President, Corporate Strategy and Development

Anthony Baldor

VP, Controller

Gloria Nam

Vice President, Investor Relations & Corporate Affairs

Michael Zanoni

Robert Kim

Vice President, Medical Director, Lung Program

Susan Limb

Senior Director Clinical Operations

Angelique Mittan

David-Alexandre Gros

Susannah Gray

Chief Scientific Officer & Therapeutic Area Head, Ophthalmology

Chief Operating Officer & Chief Technical Officer

Theresa Janke

Chief Of Staff

David Kirn

Co-Founder, President & CEO

Biotechnology Public Companies With Less Than $50M in Revenue

Western US Companies With More Than $1M in Revenue (Top 10K)

United States Public Companies With More Than 10 Employees

West Coast Companies With More Than $1M in Revenue (Top 10K)

4D Molecular Therapeutics is a biotechnology company.The Company designs, develops, and commercializes transformative gene therapeutic products for unmet medical conditions.

Post-IPO Equity - 4D Molecular Therapeutics

Series C - 4D Molecular Therapeutics

Series B - 4D Molecular Therapeutics

Cystic Fibrosis Foundation

Venture Round - 4D Molecular Therapeutics

Computer and Software Services and Scientific Services

Emeryville

California

United States

North America

Eight areas where gene therapy shines

4DMT to Participate in Upcoming Investor Conferences and Ophthalmology Innovation Summit XIV

Analyst Expectations For 4D Molecular Therapeutics's Future

4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones

4D Molecular Therapeutics downgraded at Cantor following wet AMD asset data

4D Molecular Therapeutics Fabry candidate clinical hold lifted

4D Molecular Therapeutics, Inc. (FDMT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

4D Molecular Therapeutics officer sells shares worth $49,900

4DMT Unveils More Positive Data for Wet AMD Candidate

4D Molecular Therapeutics (FDMT) Moves 11.1% Higher: Will This Strength Last?

A platform that uses directed evolution to create customized viral vectors for delivering genetic material to specific tissues for treating a range of diseases.

A primate-evolved vector designed for low dose delivery to the retina for treating retinal diseases without needing sub-retinal surgery.

A vector optimized for aerosol delivery to lung airways, capable of penetrating the mucus barrier for treating lung diseases.

A vector designed for intravenous delivery to muscle cells in the heart, offering efficient delivery and transduction for heart disease treatments.

An integrated system that drives the development of product candidates across therapeutic areas, leveraging cross-functional teams and GMP manufacturing capabilities.

In-house capabilities for GMP manufacturing of clinical trial materials, including Phase 3 and commercial scale production, and IND-enabling studies.

Japan

Asia

United Kingdom

Europe

India

Philippines

HTML5

Microsoft Outlook

GoDaddy Premium DNS

Vimeo

Wordpress

Google Compute Engine

DigiCert

F5 NGINX

Google Fonts

4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.

news impact assignment basic	general
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 25, 2024 9:06 AM	8aca5695
crunchbase profile	general	Nov 25, 2024 11:37 AM	098db213
li profile	general	Feb 4, 2024 12:51 AM	f8b52215
translate crunchbase fundingrounds	general	Nov 25, 2024 2:13 PM	af631685
peers	general	Feb 4, 2024 12:51 AM	4ee8c709
news basic	general
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:4DMOLECULARTHERAPEUTICS

4D Molecular Therapeutics Inc

Last Close

7.99

22/11 21:00

Market Cap

291.70M

Beta: -

Volume Today

2.60K

Avg: -